New research has found that a new medication, tegaserod, is effective in treating nearly all symptoms associated with chronic constipation (CC), a common disorder of the gastrointestinal tract that affects approximately 15% of the Western population at any one time. Tegaserod is currently the only drug aside from laxatives found to be effective at treating such a wide variety of symptoms. This research is published in The American Journal of Gastroenterology.
No specific cause for chronic abdominal discomfort and bowel-movement irregularity has ever been identified. Several approaches for treating CC, such as increased fiber intake and lifestyle changes are frequently used, however, evidence for their effectiveness in improving the multiple symptoms of CC is limited.
“Chronic constipation is a complex medical disorder and several bodily mechanisms are involved in its development,” says Stefan Müller-Lissner, M.D., lead author of the study. “The positive results we have found from tegaserod treatment in relieving this array of symptoms could potentially benefit millions.”
The long-term safety, efficacy and tolerability of tegaserod have been proven. Patients show no serious side-effects from long-term usage and maximal improvements were observed after approximately 6 months of further treatment and were sustained thereafter.
Sean Wagner | alfa
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
19.03.2018 | Physics and Astronomy
19.03.2018 | Materials Sciences
19.03.2018 | Event News